The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FDA grants priority review to liso-cel as a second-line therapy for R/R large B-cell lymphoma
On February 17, 2022, it was announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental biologics license application for lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, as a second-line therapy for relapsed or refractory (R/R) large B-cell lymphoma.1 The U.S. FDA has assigned a target action date of June 24, 2022.
The application was based on the pivotal phase III TRANSFORM (NCT03575351) trial, in which liso-cel demonstrated significant and clinically meaningful improvements in event-free survival over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant. The latest results from this trial have been summarized on the Lymphoma Hub, check the visual abstract here.
Liso-cel has previously received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to treat adult patients with R/R diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma Grade 3B after two or more lines of systemic therapy.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content